NDA 021588 · Novartis
Gleevec
Imatinib Mesylate · Oral
Accelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Apr 18, 2003
Approved uses
20
Original approval plus efficacy supplements
Registered trials
674
110 Phase 3, 37 recruiting
FAERS reports
27,809
20,991 serious, 6,801 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 13, 2026.
Gleevec is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with...
Mechanism: Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. In vivo, imatinib inhibits tumor growth of BCR-ABL transfected murine myeloid cells as well as...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 25, 2016 Supplement 45 · Efficacy OrphanLetterLabel
- Jan 30, 2015 Supplement 42 · Efficacy OrphanLabelLetter
- Jan 25, 2013 Supplement 37 · Efficacy · priority review LabelLetter
- Jan 31, 2012 Supplement 35 · Efficacy · priority review LetterLabel
- Apr 1, 2011 Supplement 30 · Efficacy LetterLabel
- May 27, 2009 Supplement 26 · Efficacy Letter
- Dec 19, 2008 Supplement 25 · Efficacy · priority review Accelerated approvalLetter
- Sep 26, 2008 Supplement 24 · Efficacy LetterLabel
- Sep 13, 2007 Supplement 20 · Efficacy LetterLabel
- Oct 19, 2006 Supplement 17 · Efficacy ReviewLetterLabel
- Oct 19, 2006 Supplement 13 · Efficacy ReviewLetterLabel
- Oct 19, 2006 Supplement 11 · Efficacy LetterLabelReview
- Oct 19, 2006 Supplement 14 · Efficacy ReviewLetterLabel
- Oct 19, 2006 Supplement 12 · Efficacy LabelReviewLetter
- Sep 27, 2006 Supplement 16 · Efficacy · priority review Pediatric Medical ReviewPediatric Written RequestPediatric Clinical Pharmacology Review
- Oct 20, 2005 Supplement 8 · Efficacy LetterLabel
- Mar 14, 2005 Supplement 5 · Efficacy LabelReviewLetter
- Dec 8, 2003 Supplement 2 · Efficacy ReviewLetterLabel
- May 20, 2003 Supplement 1 · Efficacy · priority review ReviewLetterLabel
- Apr 18, 2003 Original approval · Type 3 - New Dosage Form · priority review Accelerated approvalOrphanReviewOther Important Information from FDALabel
2 products under this application
- GLEEVEC · IMATINIB MESYLATE EQ 100MG BASE · TABLET, ORAL · Prescription · TE AB
- GLEEVEC · IMATINIB MESYLATE EQ 400MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Imatinib" as an intervention, any sponsor and status, largest first.
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaPivotal-lookingRecruiting
Mats HeymanAcademic, hospital or other
NCT04307576 · 6,430 participants (planned) · Start Jul 13, 2020 · Primary completion Jun 2033
Drug: Omitted Doxorubicin; Omitted Vincristine+Dexamethasone pulses and 4 more · For: Leukemia, Acute Lymphoblastic
Sites: Brussels, Belgium; Edegem, Belgium; Ghent, Belgium · 137 sites in all
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
- Treatments for COVID-19: Canadian Arm of the SOLIDARITY TrialPivotal-lookingStatus unknown
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT04330690 · 2,900 participants (planned) · Start Mar 18, 2020 · Primary completion Mar 10, 2024
Drug: Artesunate; Imatinib and 3 more · For: COVID-19
Sites: Calgary, Canada; Edmonton, Canada; Kamloops, Canada · 53 sites in all
- A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT05367765 · 2,400 participants (planned) · Start Apr 30, 2022 · Primary completion Apr 30, 2027
Drug: Flumatinib; Imatinib · For: CML, Chronic Phase
Sites: Harbin, China
- Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First RemissionPivotal-lookingCompleted
Eastern Cooperative Oncology GroupResearch network
NCT00002514 · 1,929 participants · Start May 7, 1993 · Primary completion Dec 2006
Drug: sargramostim; asparaginase and 12 more · For: Leukemia
Sites: Aurora, Colorado; Boulder, Colorado; Colorado Springs, Colorado · 94 sites in all
Heidelberg UniversityAcademic, hospital or other
NCT00055874 · 1,551 participants · Start Jun 2002 · Primary completion Mar 31, 2012
Drug: recombinant interferon alfa; cytarabine and 2 more · For: Leukemia
Sites: Aachen, Germany; Aurich, Germany; Bad Hersfeld, Germany · 66 sites in all
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsPivotal-lookingActive, not recruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT04488081 · 1,500 participants (planned) · Start Jul 31, 2020 · Primary completion Jul 31, 2028
Drug: Remdesivir; Imatinib Mesylate and 12 more · For: COVID-19
Sites: Birmingham, Alabama; Davis, California; Irvine, California · 36 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death4,640
- nausea2,144
- diarrhoea1,773
- fatigue1,533
- drug ineffective1,396
- vomiting1,291
- malaise1,082
- rash1,003
- dyspnoea995
- muscle spasms862
- neoplasm malignant847
- asthenia806
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 638 |
| 2005 | 712 |
| 2006 | 687 |
| 2007 | 717 |
| 2008 | 727 |
| 2009 | 1,136 |
| 2010 | 1,568 |
| 2011 | 3,282 |
| 2012 | 3,332 |
| 2013 | 1,010 |
| 2014 | 619 |
| 2015 | 1,009 |
| 2016 | 1,668 |
| 2017 | 1,518 |
| 2018 | 1,567 |
| 2019 | 1,761 |
| 2020 | 1,390 |
| 2021 | 1,147 |
| 2022 | 1,012 |
| 2023 | 1,022 |
| 2024 | 623 |
| 2025 | 363 |
| 2026 | 296 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Gleevec (Imatinib Mesylate)
2024 spending
$62.5M
Beneficiaries
746
6,041 claims
Per beneficiary
$83,795
$233.96 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $136,345,220 |
| 2021 | $106,443,452 |
| 2022 | $90,816,699 |
| 2023 | $73,272,881 |
| 2024 | $62,511,154 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
Hochhaus A, Wang J, Kim DW, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Jabbour E, Kantarjian HM, Aldoss I, et al. · JAMA 2024 · Clinical Trial, Phase III, Comparative Study
- Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.
Cortes JE, Hughes TP, Wang J, et al. · Blood 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.
Chiaretti S, Piciocchi A, Skert C, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Comparative Study
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
Hochhaus A, Larson RA, Guilhot F, et al. · N Engl J Med 2017 · Multicenter Study, Randomized Controlled Trial
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
Cortes JE, Saglio G, Kantarjian HM, et al. · J Clin Oncol 2016 · Clinical Trial, Phase III, Comparative Study
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.